RxDoctor Payments Data

Andrew Cushenbery

Family · Ocala, FLNPI 1467958967

Payments from drug & device makers

$1,627in general payments, 2019–2025

Across 71 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$502
  • AbbVie$367
  • Novo Nordisk$342
  • Boston Scientific$86
  • Amgen$48
  • Boehringer Ingelheim$47
  • plus $236 from 9 others

What the payments were for

  • Food & beverage$1,627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,627 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$106,580
Medicare patients
275
Services billed
3,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$42,505
JardianceEmpagliflozin23$32,269
EliquisApixaban19$27,650
FarxigaDapagliflozin Propanediol17$23,299
MounjaroTirzepatide18$22,812
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,588
RybelsusSemaglutide11$13,578
Breo ElliptaFluticasone/Vilanterol15$7,960
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$6,585
Topiramate ErTopiramate13$5,662
SymbicortBudesonide/Formoterol Fumarate13$4,551
Omeprazole190$3,469
Levothyroxine Sodium237$2,842
Gabapentin146$2,676
Atorvastatin Calcium355$2,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$342$56,08344 claims
Boehringer IngelheimJardiance$47$32,26923 claims
AstraZenecaFarxiga, Symbicort$502$27,85030 claims
PfizerEliquis$30$27,65019 claims
GSKTrelegy Ellipta, Breo Ellipta$18$23,54736 claims
AbbVieSynthroid$367$82022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.

Other family in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →